Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients (Pts) with Advanced or Metastatic Renal Cell Carcinoma (A/Mrcc) in Routine Clinical Practice

Autor: P. J. Goebell, H. Harich, E. Herrmann, T. Steiner, Michael Woike, T. Göhler, D. Kalanovic, Lothar Bergmann, U. Rebmann
Rok vydání: 2014
Předmět:
Zdroj: Annals of Oncology. 25:iv296
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu337.43
Popis: serious adverse events were observed in 72.2 % and 42.3 % of the pts (drug related in 41.3 % and 9.5% of the pts), respectively (n = 496). Most common drug-related toxicities (incidence ≥3%) of any grade were fatigue (7.3 %), rash (5.4 %), pruritus (5.4 %), nausea (4.0 %), diarrhoea (4.0 %), stomatitis (4.0 %), mucosal inflammation (3.8 %), anemia (7.5 %), thrombocytopenia (4.0 %) and peripheral oedema (3.6 %). Median progression-free survival for total patient population was 4.4 mo, for the subgroup of 1 st
Databáze: OpenAIRE